André Schrauder

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

Ursula Creutzig, Norbert Graf, Martin Zimmermann, 2013, Blood.

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia : results from Study

Ursula Creutzig, Norbert Graf, Martin Zimmermann, 2017 .

In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.

Rob Pieters, Kerrie Wilson, Heribert Jürgens, 2008, Cancer cell.

Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time

Maria Grazia Valsecchi, Adriana Balduzzi, Christina Peters, 2008, Haematologica.

Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.

Arndt Borkhardt, Christina Peters, A. Borkhardt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.

Takashi Akasaka, Martin Zimmermann, Reiner Siebert, 2010, Blood.

Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.

Thomas Flohr, Martin Stanulla, Brigitte Schlegelberger, 2005, Blood.